Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 11 (6), 870-877

Reactivation of Hepatitis C Virus and Its Clinical Outcomes in Patients Treated With Systemic Chemotherapy or Immunosuppressive Therapy

Affiliations

Reactivation of Hepatitis C Virus and Its Clinical Outcomes in Patients Treated With Systemic Chemotherapy or Immunosuppressive Therapy

Hae Lim Lee et al. Gut Liver.

Abstract

Background/aims: According to the results of several studies, the outcome of hepatitis C virus (HCV) reactivation is not as severe as the outcome of hepatitis B virus reactivation. The aim of this study was to evaluate the effect of pharmacological immunosuppression on HCV reactivation.

Methods: The medical records of patients who underwent systemic chemotherapy, corticosteroid therapy, or other immunosuppressive therapies between January 2008 and March 2015 were reviewed. Subsequently, 202 patients who were seropositive for the anti-HCV antibody were enrolled. Exclusion criteria were: unavailability of data on HCV RNA levels, a history of treatment for chronic hepatitis C, and the presence of liver diseases other than a chronic HCV infection.

Results: Among the 120 patients enrolled in this study, hepatitis was present in 46 patients (38%). None of the patients were diagnosed with severe hepatitis. Enhanced replication of HCV was noted in nine (27%) of the 33 patients who had data available on both basal and follow-up HCV RNA loads. Reappearance of the HCV RNA from an undetectable state did not occur after treatment. The cumulative rate of enhanced HCV replication was 23% at 1 year and 30% at 2 years.

Conclusions: Although enhanced HCV replication is relatively common in HCV-infected patients treated with chemotherapy or immunosuppressive therapy, it does not lead to serious sequelae.

Keywords: Hepacivirus; Hepatitis; Immunosuppression; Viral replication.

Conflict of interest statement

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

Similar articles

See all similar articles

Cited by 1 PubMed Central articles

References

    1. Boyer TD, Manns MP, Sanyal AJ, Zakim D. Zakim and Boyer’s hepatology. 6th ed. Philadelphia: Saunders/Elsevier; 2012.
    1. Seto WK. Hepatitis B virus reactivation during immunosuppressive therapy: appropriate risk stratification. World J Hepatol. 2015;7:825–830. doi: 10.4254/wjh.v7.i6.825. - DOI - PMC - PubMed
    1. Torres HA, Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol. 2012;9:156–166. doi: 10.1038/nrclinonc.2012.1. - DOI - PubMed
    1. Watanabe T, Tanaka Y. Reactivation of hepatitis viruses following immunomodulating systemic chemotherapy. Hepatol Res. 2013;43:113–121. doi: 10.1111/hepr.12014. - DOI - PubMed
    1. Jang JW, Kim YW, Lee SW, et al. Reactivation of hepatitis B virus in HBsAg-negative patients with hepatocellular carcinoma. PLoS One. 2015;10:e0122041. doi: 10.1371/journal.pone.0122041. - DOI - PMC - PubMed

Publication types

LinkOut - more resources

Feedback